Now, the company will aim to show the drug helps patients with eczema and asthma in larger, placebo-controlled trial.

So, Regeneron's revenue rose 1.9% from $3.68 billion in Q2 2025 to $3.75 billion, beating consensus estimate by $160 million ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is included among the 14 Best US Stocks to Buy for Long Term. On December 4, ...

After a series of unfortunate regulatory rejections and manufacturing issues surfaced, Regeneron’s shares dipped to $483 this ...

Sanofi and Regeneron’s Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria Approval based on phase 3 studies showing Dupixent significantly ...

Dupixent For Moderate-To-Severe Asthma Treatment Market Expected To Reach ~$8.1 Billion By 2032. December 13, 2025 7:27 am - The Dupixent market for moderate-to-severe asthma is valued at $3.25 ...

Regeneron Pharmaceuticals and Sanofi have won European Commission expanded approval of their blockbuster anti-inflammatory drug Dupixent for certain patients with the inflammatory skin condition ...

Shares of Regeneron Pharmaceuticals (NASDAQ: REGN), a biotech giant, have been southbound over the past two years as the ...

(RTTNews) - Sanofi (SNY, SNYNF, SAN.PA) and Regeneron Pharmaceuticals Inc. (REGN) announced that the European Commission has approved Dupixent (dupilumab) as a first-line targeted treatment for ...

Canaccord raised the firm’s price target on Regeneron (REGN) to $1,057 from $850 and keeps a Buy rating on the shares. The firm said they expect ...